Lakefront Biotherapeutics NV

LKFT
About the company

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

Country: BelgiumPrice: $33.98Market Cap: $2.2B

Investment snapshot

29%positive consensus
Scored 1d ago

Positive

5

BUY / PASS

Neutral / negative

6 / 5

NEUTRAL / FAIL

Median fair value

$52.20

+53.6% vs price

Models with upside

5 / 17

Positive margin of safety

Strongest signal

9 of 12 pass — Graham, Lynch and Marks object

Key risk

9 of 10 flag LKFT's cash flow — Buffett, Lynch, Piotroski +6 more

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictPASSFAILFAILFAIL · Rank #782 (Top 25.3%)NEUTRALBUYPASSNEUTRALFAILFAILNEUTRALNEUTRALNEUTRALBUYFAILBUYNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety+60.6%+49.7%+68.6%-1510.4%N/A+34.9%N/A+53.0%-1.1%-84850.0%N/A-531.6%N/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage75% pass✓ 12✗ 3▾

    9 of 12 pass — Graham, Lynch and Marks object

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.00, IC: 285.3x
    ✓BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0
    ✓Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities20.15
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=285.3x, D/EBITDA=N/A (D&A unavailable)
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0021; #420/4210 (top 10.0%)
    ✓AsnessTop 30% of eligible cross-section
  • Valuation models56% pass✓ 5✗ 4▾

    Models split on LKFT at $33.98 — fair values range $0.04–$108.06

    Graham fair value$86.17
    ✓Graham+60.6% margin vs $33.98
    Buffett fair value$67.60
    ✓Buffett+49.7% margin vs $33.98
    Lynch fair value$108.06
    ✓Lynch+68.6% margin vs $33.98
    Greenblatt fair value$2.11
    ✗Greenblatt-1510.4% margin vs $33.98
    Dreman fair value$52.20
    ✓Dreman+34.9% margin vs $33.98
    Pabrai fair value$72.29
    ✓Pabrai+53.0% margin vs $33.98
    Akre fair value$33.61
    ✗Akre-1.1% margin vs $33.98
    Marks fair value$0.04
    ✗Marks-84850.0% margin vs $33.98
    Templeton fair value$5.38
    ✗Templeton-531.6% margin vs $33.98

Where It Falls Short

  • Cash Flow10% pass✓ 1✗ 11▾

    9 of 10 flag LKFT's cash flow — Buffett, Lynch, Piotroski +6 more

    Free Cash Flow Proxy$-405.0M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-318.5M
    ✗LynchPositive and growing
    Operating Cash Flow$-302.4M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-7.56%, ROA=9.42%
    ✗PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldP/E=5.9x, FCF Yield=-14.2%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive2/11 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-14.2%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency2/11 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-318.5M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-14.23%; #3375/4519 (top 74.7%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Profitability19% pass✓ 13✗ 22▾

    13 of 16 flag LKFT's profitability — Graham, Buffett, Lynch +10 more

    Positive EPS (10 years)5/12 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)5/12 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)1.5%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)26.5% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-405.0M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)P/E 5.9x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE9.9%
    ✗Lynch> 15%
    EBIT / Enterprise Value16.2%
    ✓Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=16.2%, ROC=10.1%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets9.42%
    ✓PiotroskiROA > 0
    ROA Change YoY1.79% -> 9.42% (delta: +7.63%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-7.56%, ROA=9.42%
    ✗PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY87.4% -> 97.3%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue27.1%
    ✓Dreman>= 8%
    Net Income / Shareholders' Equity9.9%
    ✗Dreman> 12%
    Margin of SafetyP/E=5.9x, P/B=0.6x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity6.7% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic Value34.9% (IV=$52.20 vs Price=$33.98)
    ✓Marks>= 20% below intrinsic value
    Positive Net Income Frequency5/11 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue26.5%
    ✓Ackman>= 15%
    Net Income / Shareholders Equity9.9%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-36.8% (2023) -> 26.5% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendrevenue up, operating margin -36.8% -> 26.5%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+16.83%; #326/6340 (top 5.1%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+31.78%; #1330/3702 (top 35.9%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity+9.92%; #1824/5226 (top 34.9%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0495; #2566/5884 (top 43.6%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR-16.0% over 5 years
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years5/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Growth38% pass✓ 7✗ 6▾

    5 of 8 flag LKFT's growth — Graham, Lynch, Marks +2 more

    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)P/E 5.9x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: -50.4% vs Rev: 355.5%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$-3.63 (2015) -> $5.72 (2025)
    ✓DremanPositive over recent years
    EPS CAGR18.9% CAGR over 9 years
    ✓Dreman> 5% annualized
    Positive Net Income Frequency5/11 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth8.1%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency3/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendrevenue up, operating margin -36.8% -> 26.5%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR17.3%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR-16.0% over 5 years
    ✗Neff7%-20% annualized
  • Efficiency38% pass✓ 4✗ 7▾

    5 of 8 flag LKFT's efficiency — Buffett, Greenblatt, Munger +2 more

    Current Ratio20.15
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-0.2%
    ✗Buffett> 10%
    ROIC - WACC-10.2%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)10.1%
    ✗Greenblatt> 25%
    Current Ratio Change YoY9.97 -> 20.15
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.07x -> 0.33x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities20.15
    ✓Dreman> 1.5
    Return on Invested Capital7.2%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-2.5%; FY2024: ROIC=-5.1%; FY2025: ROIC=7.2%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC7.2% (RR=100% x ROIC=7.2%)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/3 years above 12% (latest 7.2%)
    ✗SleepROIC > 12% in a majority of years
  • Verdicts45% pass✓ 5✗ 6▾

    Split decision: 6 NEUTRAL · 5 FAIL · 3 BUY · 2 PASS

    Overall verdict
    ✓GrahamPASS (5/9)✗BuffettFAIL (2/9)✗LynchFAIL (2/7)✗GreenblattRank #782•PiotroskiNEUTRAL (F-Score 7)✓DremanBUY (8/11)✓MungerPASS (2/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (2/6)✗MarksFAIL (2/5)•AckmanNEUTRAL (6/9)•TempletonNEUTRAL (5/8)•SleepNEUTRAL (4/6)✓AsnessBUY (Rank #92/2370 (Top 3.9%))✗NeffFAIL (2/6)✓SchlossBUY (5/7)•OshaughnessyNEUTRAL (Not ranked)
  • Valuation46% pass✓ 19✗ 9▾

    7 of 13 flag LKFT's valuation — Lynch, Greenblatt, Dreman +4 more

    Price / 3-yr avg EPS9.8x
    ✓Graham<= 15x
    Price-to-Book Ratio0.6x
    ✓Graham<= 1.5x
    P/E x P/B5.80
    ✓Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)P/E 5.9x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value16.2%
    ✓Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=16.2%, ROC=10.1%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS5.9x
    ✓Dreman< 12x✓Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per Share0.6x
    ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessP/E=5.9x
    ✓MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=5.9x, FCF Yield=-14.2%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=5.9x, P/B=0.6x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic Value34.9% (IV=$52.20 vs Price=$33.98)
    ✓Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low148% of trailing low ($23.00)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+16.83%; #326/6340 (top 5.1%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+1.6976; #794/6449 (top 12.3%)
    ✓AsnessTop 30% of eligible cross-section
    Price / Diluted EPS5.9x
    ✓NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share0.59x
    ✓SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change+14.9%
    ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.5835; #2415/5247 (top 46.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-14.23%; #3375/4519 (top 74.7%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+19.86%; #1355/6202 (top 21.8%)
    ✗OshaughnessyTop 10% of eligible cross-section

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Mid Cap($2.2B)
Revenue: $1.3B+355.5% YoY
Net Income: $377.0M+389.0% YoY

Financial Snapshot

Operating Margin26.5%
Return on Equity9.9%
Debt / Equity0.00
Current Ratio20.15
EPS (Diluted)$5.72+390.9% 1y
Shares Retired0.0% / 0.0% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2025

Retired 0.0% of shares last year, 0.0% over two.

Buybacks
—
Dividends
—

What drove EPS

A buyback raises earnings per share without the company earning more. This splits each year's change into the two.

FY24
−67.2% = −67.1% + −0.3%
FY25
390.9% = 389.0% + 0.4%
Earnings Fewer shares More shares

The two parts do not sum exactly to the total — the difference is the cross-term, plus preferred capital where the company has any. It is left visible rather than distributed into the other two.

Share count is the denominator the filer used for diluted EPS, recovered as net income ÷ EPS — not the balance-sheet count, which is a point-in-time figure and would put the timing difference into this split. Years with a loss are omitted: a smaller share count makes a loss per share larger, so the decomposition inverts.

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

MetricFY 2025
Sources
  • 20-F · 2026-03-26
FY 2024
Sources
  • 20-F · 2025-03-27
FY 2023
Sources
  • 20-F · 2024-03-28
FY 2022
Sources
  • 20-F · 2023-03-23
FY 2021
Sources
  • 20-F · 2022-03-24
Market Cap$2.2Bcurrent$1.5Best.$2.5Best.$2.9Best.$4.4Best.
Revenue$1.3B↑356%$286.8M↑8%$265.3M↑3%$257.2M↑4%$246.6M
Operating Income$346.6M↑277%-$196.0M↓101%-$97.7M↑30%-$139.7M↑23%-$180.5M
Net Income$377.0M↑389%$77.1M↓67%$234.3M↑201%-$232.4M↓114%-$108.6M
EPS (Diluted)$5.72↑391%$1.17↓67%$3.55↑200%$-3.54↓113%$-1.66
Gross Margin97.3%↑11%87.4%—95.0%↓4%99.3%
Operating Margin26.5%↑139%-68.3%↓86%-36.8%↑32%-54.3%↑26%-73.2%
ROE9.9%↑288%2.6%↓66%7.6%↑188%-8.6%↓121%-3.9%
Total Debt$8.1M↓33%$12.2M↑15%$10.6M----
Shareholders' Equity$3.8B↑26%$3.0B↓3%$3.1B↑15%$2.7B↓3%$2.8B
Current Ratio20.15↑102%9.97↑11%9.02↑11%8.11↓6%8.58
Debt / Equity0.00↓47%0.00↑18%0.00——
Operating Cash Flow-$302.4M↑9%-$333.0M↑26%-$449.3M↑16%-$533.6M↓1%-$530.1M
Free Cash Flow-$318.5M↑9%-$350.4M↑25%-$470.0M↑16%-$562.8M↑4%-$587.1M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

LKFT vs Peers — Financial Grading

Revenue$1.3BMedian
Net Income$377.0MMedian
ROE9.9%Median
D/E0.00Top 25%
Op. Margin26.5%Top 25%
Curr. Ratio20.15Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11